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 Infective endocarditis (IE) is a bacterial infection that has existed for multiple centuries 
and is a disease that has been constantly evolving. Recently, cases of IE caused by Staphylococcus 
aureus have been increasing gradually. To add to the problem, little is known about the mechanism 
in which S. aureus causes the heart infection. This study examined four different receptor proteins 
within the microbial surface components recognizing adhesive matrix molecules (MSCRAMM) 
family (ClfA, ClfB, FnbpA, FnbpB), that are present on the cell wall of S. aureus to understand 
each of their role when binding to fibrinogen (Fg), a key ligand in human hosts. The differences 
in binding to Fg for 7 different clinical isolates of S. aureus were analyzed using a 96-well 
microtiter plate apparatus. The binding to Fg for 5 reference strains of S. aureus (Newman strains 
and 8325-4) were also examined in the study. It was determined that the Newman strain that lacked 
ClfA had lower absorbance readings, indicating lower binding, than ones with ClfA and ones that 
lacked ClfB. In addition, clinical isolates, with an exception of one, exhibited comparably higher 
absorbance readings, indicating enhanced binding, relative to the Newman strains. The results 
pointed out that ClfA plays a critical role when binding to Fg, and both FnbpA and FnbpB are also 
equally important. Furthermore, it was discovered that the origin of the clinical isolates impacted 
binding to Fg. S. aureus specimens from the nasal cavity had lower absorbance readings compared 




Infective endocarditis (IE), a bacterial infection of the endocardial surface, was first 
described in 1885 by William Osler [12]. Since then, the disease has been evolving in various ways 
and has become a disease that is seen more commonly throughout the world. Today, IE affects 3 
to 10 per 100,000 per year and there are 40,000 to 50,000 new cases each year just within the 
United States [1]. IE epidemiology has changed over the last several decades where now, the 
patient demographic is older (mean age 57.2) and prominently men (66.3% in the early 2000s) 
[12]. Furthermore, the microbiology of the IE seen today has changed. S. aureus has become the 
most common causative agent where it accounts for over 30% of all cases [1]. Enterococcal IE 
along with coagulase-negative staphylococcal IE have also increased over the years. On the other 
hand, Streptococcus viridans IE has decreased in percentage over the span of five decades, but is 
still the causative agent for approximately 20% of all cases [12]. While certain changes have been 
observed with IE over the years, many characteristics of the disease are still uncertain. To begin 
with, the general method of infection development is understood to some extent, but it is unclear 
how exactly the bacteria cause the infection within the heart.  
The development of the disease can be subdivided into three steps. The initial step is 
bacteremia, where the bacteria enters the bloodstream through the mouth, gastrointestinal tract, 
skin, or urinary tract. Although less common, venous catheters as well as surgeries are also 
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methods of entry into the bloodstream. In the second step, the bacteria adhere to the endocardial 
surface. Normal endothelial lining of the heart is resistant to the adherence of bacteria; however, 
damaged or abnormal endocardial surfaces allow the binding of the bacteria [1]. Host proteins 
such as fibrin, which is composed of polymerized fibrinogen molecules, help the bacteria to bind 
to host or artificial (e.g. implanted) surfaces [3]. The last step is the development of biofilms where 
with quorum sensing and synchronized gene expression, the bacteria successfully assemble and 
go through maturation. Once biofilms are developed, these bacteria are protected from the host 
immunity and are extremely difficult to kill with antibiotics.  
IE can be classified differently according to anatomical site (left/right side), diagnosis 
status (definite/possible), causative microbial agent, and whether it is a native valve IE or 
prosthetic valve IE (PVE). Among these different classifications of IE, PVE is a public health 
challenge that must be addressed urgently due to its high morbidity and mortality rates potentially 
caused by the obstacles faced with diagnosis and treatment. With the advancements in diagnosis 
and treatment, the mortality rate of PVE has in fact decreased to 22.8% by the beginning of the 
21st century [8]. Nevertheless, despite improvements in diagnosis and treatment methods for PVE, 
the optimal methods are still under debate. Currently, the diagnosis of PVE is based upon positive 
blood culture and detection of vegetation, paravalvular abscess, fistula, or valve dehiscence 
through echocardiography [8]. As for treatment, antibiotic prophylaxis and/or early surgical 
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treatment is recommended [1]. Promising results with these methods have been observed in 
numerous cases, but there are still many complications with them as well. 
To develop better diagnosis and treatment methods for PVE, more research must be 
conducted on the microbial agents from various perspectives. One approach focuses on 
MSCRAMM (microbial surface components recognizing adhesive matrix molecules) of S. aureus. 
This gram positive, opportunistic pathogen is the most common microorganism that causes PVE 
and other IEs. MSCRAMMs are known to be the main virulence factor that allows S. aureus to 
bind to proteins within the heart such as fibrinogen (Fg). If more research on these adhesive matrix 
molecules are conducted and the mechanism of them become apparent, the results could be used 
to develop new strategies to lower PVE incidence and mortality rates. This study, therefore, 
focused on four MSCRAMM (FnbpA, FnbpB, ClfA, and ClfB) from S. aureus to understand their 
functions and structures that could be contributing toward the binding to Fg.  
These MSCRAMMs contain a signal sequence, the ligand-binding A region composed of 
three domains (N1, N2, and N3), the serine-aspartate repeat region (R region), and the C-terminal 
that is needed for cell wall anchoring (Figure 1). The A region is responsible for the Fg binding 
mechanism termed “Dock, Lock, and Latch” [7]. The Fg ligand docks into the trench located 
between the N2 and N3 domains and the C-terminal extension of the N3 domain moves over to 
the the ligand peptide to “lock” it in place [4].  
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Multiple MSCRAMMs all contribute to the binding process to Fg. However, little is 
known about the mechanism that allows S. aureus to bind to fibrinogen within the human body. 
This current study was conducted to understand the effects that the four MSCRAMMs chosen for 
the study, which were FnbpA, FnbpB, ClfA, and ClfB, have during the Fg-interaction through 
experimentation results with fibrinogen. The genetic compositions of each MSCRAMM were also 
examined to determine whether the unique gene sequences of the MSCRAMM allow some isolates 
of S. aureus to bind stronger to fibrinogen. Furthermore, relationships between clinical isolates 
collected from the nose and isolates obtained from the bloodstream were also analyzed since 
healthcare providers are currently very interested in differences observed for bacterial isolates 
collected from different locations in the human body.  
METHODS AND PROCEDURE 
Selection of bacteria samples: Specific clinical specimens of S. aureus were selected for 
these studies. Several criteria were utilized to select these particular isolates. The first and most 
important criteria when deciding the isolates was the amino acid sequences at the C-terminus of 
the subdomain N3. The C-termini of N3 for ClfA, ClfB, FnbpA, and FnbpB all play an important 
role during the “lock, dock, and latch” mechanism used by S. aureus to bind to fibrinogen. During 
the binding process, the C-terminus of N3 goes through a conformational change and this allows 
S. aureus to lock the peptide ligand into the trench between N2 and N3 [5].  
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The amino acid sequences of the A domain for both FnbpA and FnbpB were first analyzed 
and the samples were reorganized into groups with the same N3 C-termini. From this analysis, it 
was determined that the C-termini were the same for samples within the same bacterial lineage, as 
estimated by their clonal complex (Figure 2). The list was then compared with the list of samples 
that was, at that time, available in the lab’s -80°C freezer. Samples that existed on both list and 
belonged to different locations of collection (anterior nares or bloodstream) were chosen. When 
selecting the samples, the clonal complex of the samples were also noted to make sure to have 
samples that exist in the same clonal complex, but were also clinically different in terms of whether 
the sample came from the blood or the nose.  
Clinical samples are important to analyze because these are the ones associated with the 
diseases. However, their genomes are not well characterized as type strains or reference strains.  
Therefore, numerous reference strains were analyzed concurrently to provide a benchmark. Four 
different Newman strains of S. aureus were selected: Newman wild, ΔClfA, ΔClfB, and ΔClfA 
and ClfB. The wild-type S. aureus (8325-4) and negative mutants for the Fnbps (ΔFnbpA and 
ΔFnbpB) were also examined; however, the results conveyed that the negative mutants were not 
as critical in binding to Fg as the clumping factor proteins (see Results section). 
The S. aureus samples of 8325-4 (wild), 250 (CC97 CDC), 172 (CC8 CDC), 3450 (CC8 
CDU), 4495 (CC8 CDI), 289 (CC5 CDC), 3854 (CC5 CDU), 204 (CC5 CDC), Newman wild, 
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Newman ΔClfA, Newman ΔClfB, and Newman ΔClfA and ClfB were used for the experiment.  
CDC stands for cardiac device control, and these isolates were obtained from the nares of healthy 
patients with a cardiac device. CDI and CDU were obtained from the bloodstream of patients with 
infected (CDI) or uninfected (CDU) cardiac implants, where “infection” was defined clinically.   
Use of microtiter plate assay for adhesion: Two days prior to the experimentation date, 
100µl of 100µg/ml Fg solution were poured into each well of the microtiter plate. The number of 
wells used per plate differed every experiment since the number of samples being examined were 
different each time. The microtiter plate was incubated at 4°C for 24 hours. The plate was rinsed 
with PBS 3x followed by 200µl of 2% BSA which were poured into the same wells. After another 
24 hour incubation period at 4°C, the wells were rinsed with PBS 3x again.  
S. aureus isolates and reference strains were grown in tryptic soy broth (TBS) 
supplemented with 0.25% dextrose, incubated at 37°C at 200 rpm for 12 hours, passed to fresh 
TBS, and then left in TBS with 0.25% dextrose to grow until OD550 of 0.540 ± 0.05. Once the 
required absorbance level was observed, the solutions were placed into 2 centrifuge tubes and the 
bacteria was isolated from TBS through centrifugation at 5000 rpm for 3 minutes in 4°C. The 
resulting pellets were then combined into one tube with the usage of PBS. The PBS solution was 
then diluted until 1.000 at OD600.  
An amount of 50µl of the diluted bacteria were injected into 4 wells of the microtiter plate. 
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Then the 96 flat-well bottomed microtiter plate was incubated at 37°C for 90 minutes. After the 
incubation period, each well of the plate was rinsed with 4°C PBS 3x. 100µl of 2.5% formaldehyde 
was poured into each well and after the aspiration of the formaldehyde, 200µl of crystal violet was 
poured into each well. PBS was then used to rinse the wells 6x in total. Finally, 100µl of DMSO 
was added to each well and the microtiter plate was analyzed through Gen5™ Microplate Reader 
and Imager Software at OD620. The analysis with the Gen5™ Microplate Reader was conducted 
in triplicate for each plate.  
Analysis of absorbance readings: Absorbance readings of the reference strains and 
clinical isolates collected from numerous experimentation dates were combined together to find 
the median and standard deviation for each sample. The median for the samples were then used in 
two-tailed t tests where the absorbance reading of wild-type strain 8325-4 was compared with 
other sample absorbance readings. In this study, a p-value < 0.05 was considered to be significant.  
RESULTS 
When S. aureus Negative (ΔFnbpA and ΔFnbpB) was originally tested with clinical 
isolates and the wild-type of S. aureus (8325-4), it produced higher absorbance readings than 
expected. In one experiment, the absorbance reading median at 620 nm for S. aureus Negative was 
0.7280. This reading was higher than the S. aureus wild (8325-4) in the same experiment (0.6950). 
High absorbance readings, such as the one observed with S. aureus Negative, indicate that more 
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cells were able to attach to the wells. In the human body, this translates to the idea of more S. 
aureus attaching to fibrinogen and increasing the chance of causing an infection such as IE. 
Absorbance readings, therefore, were indirectly measuring bond strength. Severity of IE and 
higher absorbance readings, on the other hand, have not been associated together in past studies, 
but it is an educated assumption that can be made. The original intention to use S. aureus Negative 
was to have a strain with an absorbance reading similar to the blank. Since it lacked the qualities 
that were needed, the S. aureus Negative was replaced by the Newman strains in later experiments. 
The Newman strains produce FnbpA and FnbpB; however, they are not expressed on the cell walls 
[6]. Therefore, the wild-type strain of Newman was a good reference to use to compare against the 
clinical isolates. Furthermore, the Newman strains that lacked either ClfA, ClfB, or both were good 
to understand the role of the clumping factors during the binding process to fibrinogen.  
The median absorbance readings were determined for both clinical isolates and Newman 
strains from numerous experiments (Table 1). While apparent characteristics could be observed 
among the Newman strains, no distinct and clear association among clonal complexes or clinical 
isolates could be established from the data. The approach of taking absorbance readings for each 
sample and finding the median, however, yielded inconsistencies because of instrumental drift, 
and the absorbance readings for the same bacterial sample varied greatly depending on the 
experimentation day. Therefore, relative absorbance readings were also determined by using 
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absorbance readings of the Newman wild cells as the reference for each day. The median of the 
differences for each bacterial specimen were determined (Table 2). In Figure 3, the x-axis 
represents the absorbance reading of the wild Newman strain at 620 nm and the bars represent 
whether the absorbance reading for the sample strain was higher or lower than the reference strain. 
Wild-type Newman was chosen to be the standard because while it possesses ClfA and ClfB, they 
do not have FnbpA and FnbpB expressed on their cell walls [6]. It was the ideal strain to use when 
interpreting the binding characteristics of each of the clinical isolates because before any analysis, 
it was believed that fibronectin binding proteins were more important during the binding process.  
Two-tailed t tests between absorbance readings of each bacterial specimen and the S. 
aureus wild (8325-4) were also conducted (Table 3). The wild-type strain S. aureus (8325-4) was 
used for the t tests instead of Newman wild because many previous studies have used this strain 
as a reference strain due to its low number of mutations and for commonly existing in natural 
conditions. Moreover, wild strain 8325-4 express all four MSCRAMMs (FnbpA, FnbpB, ClfA, 
and ClfB) examined in the experiment [2 and 12]. Comparing the Newman strains and clinical 
isolates with S. aureus wild (8325-4) would convey whether the compared specimen had a 
mechanism that allowed them to bind more to fibrinogen or a mechanism that prevented them from 
binding to fibrinogen. Absorbance readings of all samples except Newman wild and Newman 




S. aureus is known to cause various infections within the human body and infective 
endocarditis (IE) is one of the many S. aureus infections that could be life-threating. Although the 
number of IE cases caused by S. aureus have been increasing over the past couple of decades, little 
is still known about how these microbes are able to bind inside the human body to cause infections. 
One theory is that IE is linked to the binding associated with MSCRAMMs on S. aureus. This 
study focused on fibronectin binding proteins A and B as well as clumping factors A and B.  
One apparent observation with the Newman strains was that a lower absorbance reading 
was obtained for Newman ΔClfA strains than for Newman ΔClfB strains (Figure 4). This indicates 
that ClfA is more important for binding to fibrinogen than ClfB, at least for this reference strain. 
This difference between Newman ΔClfA and Newman ΔClfB is supported by findings from 
previous experiments, which indicate that ClfA has a greater role than ClfB when binding [2 and 
9]. Furthermore, these past works show that ClfA masks the binding through ClfB [2 and 9]. 
Newman ΔClfA lacks ClfA so it would, in theory, have diminished binding affinity to fibrinogen 
than a sample that only lacks ClfB. The difference between these two clumping factors lies within 
the A domains and this may explain why ClfA has a greater effect when binding than ClfB.  
Both ClfA and ClfB have similar structures in terms of signal sequence and wall 
attachment domains; however, only 26% of their A domains overlap [2]. The specific amino acids 
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that are responsible for making the effects of ClfA more significant are unknown, but this 
observation suggests that if the limited but existing similarities of both clumping factors can be 
targeted, both ClfA and ClfB will be prevented from functioning simultaneously.  
Other observations from the experiment with the Newman strains can also be used to 
explain the relationship between ClfA and ClfB. Figure 4 suggests that the absorbance reading for 
Newman ΔClfA and Newman ΔClfB approximately adds up to the absorbance reading of the wild-
type Newman strain. Figure 3, on the other hand, portrays the same concept from a different 
perspective. In this graph, the sum of the relative absorbance reading for Newman ΔClfA and the 
relative absorbance reading for Newman ΔClfB is approximately the same as the relative 
absorbance reading for Newman ΔClfA and B. These two observations point out that although 
ClfA has more significance during the binding process, both ClfA and ClfB are necessary 
MSCRAMMs for S. aureus to successfully bind to fibrinogen.  
The results for the clinical isolates were more challenging to interpret (Figure 5). Unlike 
Newman strains that lack fibronectin binding proteins on their walls, these isolates have both 
fibronectin binding proteins as well as clumping factor proteins (Figure 6). Figure 3 provides an 
interesting comparison between the Newman strains and the clinical isolates. In this figure, the 
positive bars convey that the sample being compared has a higher absorbance reading than 
Newman wild while the negative bars state the opposite. With the exception of isolate #289 (CC5 
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CDC), all clinical isolates, including 8325-4, had positive values while all Newman strains had 
negative values.  
This graphical characteristic suggests that all four MSCRAMMs examined in this study 
(FnbpA, FnbpB, ClfA, and ClfB) are necessary when binding to fibrinogen. While ClfA and ClfB 
are expressed in Newman strains and clinical samples, the Newman strains do not have FnbpA and 
FnbpB anchored on their cell walls [6]. Enhanced binding for most of the clinical isolates, which 
have fnbA and fnbB, suggests these two proteins are also critical for Fg-binding (Figure 6). 
Newman strains do in fact have both fnbA and fnbB; however, they have a nonsense mutation that 
results in the truncation of both Fnbps at the end of the C domain at identical locations. Previous 
experiments show that the truncated Fnbps are completely secreted into the culture medium and 
do not anchor to the cell walls of S. aureus since they lack the sortase motif (LPETG) [6].  
 When this relationship between the MSCRAMMs is viewed from a larger perspective, 
the same concept applies. Past studies point out that both fibronectin binding proteins and 
clumping factors are critical to initiate endocarditis [10]. Experimentation results have showed that 
both promote valve colonization, but it was also discovered that they have different roles during 
the colonization process. While ClfA promotes only early valve colonization, FnbpA is responsible 
for promoting both colonization and persistence, causing clinical symptoms commonly seen with 
S. aureus infections [10]. Even in the clinical aspect, both Fnbps and Clfs are critical components. 
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It is worth mentioning that the A domains of FnbpA and ClfA of S. aureus wild (8325-4) 
have ~ 24.8% amino acid identity and have ~ 46% amino acid similarity in the Fg binding regions. 
In addition, FnbpA and ClfB from the same sample have ~ 27.8% amino acid identity while they 
have ~ 49% amino acid similarity in the Fg binding regions [13]. These observations suggest that 
fibronectin binding proteins have similar structures to clumping factors, but also have additional 
structures not observed in clumping factors that promote binding to fibrinogen and are necessary 
to have a successful binding.  
From a different approach, the clinical isolates also suggest an interesting point about 
themselves. In a two-sample t test where the clinical isolates were separated into two groups for 
analysis, nasal isolates (CDC) vs. bloodstream isolates (CDI and CDU), it was determined that 
there was significant difference between the two groups (p = 0.0003117). The grouping suggests 
that the origin of the S. aureus sample is critical. CDC are samples collected from the nasal cavity 
of patients with S. aureus while both CDI and CDU are samples collected from the bloodstream 
of patients with S. aureus. The result from the two-sample t test suggests that S. aureus that 
primarily resides in the nasal cavity (CDC) has a lower binding affinity to fibrinogen than S. aureus 
that is present in the bloodstream.  
One possible reason for this result is due to the existence of various ligands in the nasal 
cavity in which S. aureus can bind to. The uppermost layer of epidermis of the nasal cavity is 
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composed of stratum corneum and this layer contains keratinocytes that express numerous proteins 
like loricrin, cytokeratin 10, and involucrin. Out of the many proteins expressed in the nasal cavity, 
loricrin and cytokeratin 10 are two ligands that ClfB frequently binds to [11]. This suggests that 
binding to fibrinogen may not be important for nasal isolates of S. aureus. and S. aureus classified 
as CDC may have more ClfB expressed on their cell walls rather than the other MSCRAMMs 
because ClfB is necessary for nasal colonization.  
Furthermore, the lower binding affinity towards fibrinogen can be explained here too 
because, as mentioned in an earlier analysis with Newman strains, ClfA contributes more greatly 
towards the binding to fibrinogen than ClfB. If it is assumed that CDC strains have more ClfB 
expressed than ClfA, it makes sense to make the assumption that nasal isolates cannot bind as 
efficiently as bloodstream isolates to fibrinogen due to lower ClfA count. On the other hand, the 
reason why CDU and CDI strains had higher binding affinity to fibrinogen than CDC strains could 
be due to high count of ClfA. High ClfA count can be assumed since both CDU and CDI strains 
are samples from the bloodstream and blood has high concentrations of complement factor I and 
fibrinogen – two proteins that ClfA binds to [3]. To survive in the bloodstream and successfully 
cause infections, ClfA would therefore be necessary. Further research must be conducted to 
conclude that there are more ClfA counts on CDU and CDI strains while there are more ClfB 
counts on CDC with Western blotting and ELISA, but for now, it is the best conclusion to make in 
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regard to why CDC strains had lower binding affinity toward fibrinogen than CDI and CDU. 
 From the Newman strains, the role in which the clumping factors play during the binding 
process became apparent. As previous studies had suggested, ClfA had a more significant role 
during the binding process to fibrinogen, but ClfB was also necessary. In addition, the Newman 
strains also suggested that fibronectin binding proteins may be equally important during binding. 
On the other hand, little could be concluded about the clinical isolates. Although samples 
belonging in the same clonal complex had identical sequences for all four MSCRAMMs 
experimented, binding affinity to fibrinogen varied greatly and had no apparent correlations. There 
was, however, significant difference in binding affinity between isolates from the anterior nares 
and bloodstream. CDC strains did not bind as much as the other two clinical isolates and this was 
associated with the difference in types of ligand available. Further research must be conducted to 
interpret what type of MSCRAMM are expressed on each clinical isolate type as well as how much 
are expressed for each type. Moreover, how physical stress affects each MSCRAMM should also 
be examined since it is important to understand how these MSCRAMM tested in this study help 
S. aureus in an environment where blood will be constantly be flowing. The findings made in the 
current study, however, can be utilized in the near future for faster intervention toward people who 
are at risk of developing IE. Patients with artificial valves and S. aureus bacteremia should be 
treated as soon as possible to prevent possible IE development because compared to S. aureus 
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residing in the nasal cavity, ones present in the bloodstream will more likely bind to fibrinogen 
and would eventually develop into IE. On the other hand, treatment methods that target both 
clumping factors and fibronectin binding proteins concurrently is recommended when treating 
against IE. Both types of MSCRAMMs are factors that are equally important when preventing S. 
aureus from colonizing in the heart valve.   
CONCLUSION 
Infectious endocarditis caused by S. aureus is currently a growing public health concern 
throughout the world that can no longer be simply ignored. To make matters worse, cases of IE 
caused by MRSA have also been steadily growing. S. aureus infections, especially IE, are 
preventable and last resorts such as surgeries can be avoided if proper measures are taken ahead 
of time. In order to create prevention measures, the structures of each MSCRAMM expressed on 
S. aureus along with their roles during the binding to Fg must be analyzed more thoroughly. Little 
about S. aureus is known to the scientific world today, but with the future experiments on various 
aspects of their binding mechanism, more preventative public health measures can be taken 









Figure 1: Illustration of (a) FnbpA/B and (b) ClfA/B from S. aureus Newman. The N-terminus 
has a signal sequence and is followed by the A domain. For both MSCRAMM, the A domains 
bind to fibrinogen. The repeat region in FnbpA/B that follows allows S. aureus to bind to 
fibronectin. On the other hand, ClfA/B has a Ser-Asp repeat region. The C-terminus for both 
have a proline-rich repeat (PRR), wall (W), and membrane (M)-spanning domains. The numbers 



























Figure 2: Amino acid sequence of FnbpA A domain and F1 region from 8325-4 and the clinical 
isolates. Red indicates the signal sequence, yellow shows the difference in amino acid with the 
reference 8325-4 strain, and blue is the insertion (ADD) or deletion (DEL) from the 8325-4. 
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Table 1: The table contains the median absorbance readings at 620 nm for both clinical isolates 
and reference strains. 
S. aureus sample absorbance reading median at 620 nm 
Newman ΔClfA 0.1955 
Newman ΔClfB 0.5670 
Newman ΔClfA ΔClfB 0.1410 
Newman wild 0.5955 
8325-4 (wild) 0.4845 
250 (CDC - CC97) 0.5560 
172 (CDC - CC8) 0.6125 
289 (CDC - CC5) 0.7520 
204 (CDC - CC5) 0.5200 
3854 (CDU - CC5) 0.6470 
3450 (CDU - CC8) 0.3300 













Table 2: Table consists of median relative absorbance readings using wild-type S. aureus 
Newman. S. aureus Newman readings were subtracted from sample readings.  
S. aureus sample relative absorbance reading at 620 nm 
Newman ΔClfA -0.4125 
Newman ΔClfB -0.0555 
Newman ΔClfA ΔClfB -0.5100 
172 (CDC - CC8) 0.0370 
250 (CDC - CC97) 0.0295 
289 (CDC - CC5) -0.0770 
3854 (CDU - CC5) 0.1255 
4495 (CDI - CC8) 0.1365 














Table 3: Table with p-values obtained from two-tailed t tests conducted between median 
absorbance readings of S. aureus wild (8325-4) and absorbance readings of both clinical isolates 
and Newman strains. p-values lower than 0.05 are considered significant and are interpreted that 
there is a significant difference between absorbance readings of S. aureus wild (8325-4) and the 
compared S. aureus specimen. 
S. aureus sample p-value  
Newman ΔClfA 2.8280E-8 
Newman ΔClfB 0.1111 
Newman ΔClfA ΔClfB 1.2700E-9 
Newman wild 0.6689 
250 (CDC - CC97) 1.7169E-7 
172 (CDC - CC8) 6.5172E-5 
289 (CDC - CC5) 2.7706E-6 
204 (CDC - CC5) 0.0002 
3854 (CDU - CC5) 1.8165E-6 
3450 (CDU - CC8) 2.5060E-8 









Figure 3: Relative absorbance reading using wild-type S. aureus Newman as the baseline. The 
sample and S. Newman came from the same column in the microtiter plate. The x-axis represents 
the wild-type S. Newman’s absorbance reading. The yellow bars represent strains that had a 
smaller absorbance reading than the reference strain while the blue bars represent strains that had 
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Figure 4: Graphical representation of the absorbance readings taken at 620 nm. While Newman 
ΔClfA and B have the lowest absorbance reading, Newman ΔClfA also has a very small 
























































Figure 5: Graphical representation of absorbance readings of clinical isolates grouped by (a) 
bacterial lineage (i.e. clonal complexes) as well as (b) clinical isolate groups. The gray and 
golden yellow for both graphs represent the blank control and S. aureus wild (8325-4), 
respectively. In (a) purple represents clonal complex (CC) 97, pink is CC8, and red is CC5. For 
(b) light orange represents CDC, light green represents CDU, and light blue represents CDI. 


















































































Figure 6: Schematic representation of MSCRAMM attached on the walls of S. Newman and S. 
aureus 8325-4. While both strains produce Fn-binding proteins and clumping factors, Newman 
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